Momentum Builds For PCSK9 Class, But Proof Of Safety Still Thin

Amgen’s Phase II program for its PCSK9 inhibitor AMG 145 impresses when it comes to lowering cholesterol. But the studies were only 12 weeks long and the bigger test for monoclonal antibodies like AMG 145 and Sanofi/Regeneron’s rival REGN727 is proof of longer-term safety in bigger trials.